Why this study matters
Fundus albipunctatus is an inherited retinal disease most often associated with changes in the RDH5 gene. People with RDH5-related disease commonly experience night blindness and may have distinctive white-yellow spots across the retina. For some individuals, the condition can also involve degeneration in the macula—the central retinal region responsible for detailed vision.
RDH5 is active in the retinal pigment epithelium (RPE), a supportive cell layer beneath the light-sensing photoreceptors. The protein it produces is part of the visual cycle, the process that regenerates 11-cis-retinal, a molecule required for visual pigment and vision after light exposure. When RDH5 is not working properly, this regeneration step is disrupted. The result can be slow recovery of vision in dim light and, in some patients, progressive central retinal changes.
A 2026 study in Investigative Ophthalmology & Visual Science reports encouraging preclinical results from a gene augmentation approach designed for RDH5-associated retinopathy. Importantly, the work was performed in cats with both copies of the RDH5 gene inactivated (RDH5-/-), providing a large-animal model in which researchers could examine both retinal function and retinal structure.
The gene therapy approach
Gene augmentation therapy aims to deliver a working copy of a gene to cells that need it. In this study, the research team used an adeno-associated virus (AAV), a commonly used gene-delivery vehicle, to carry feline RDH5 complementary DNA (cDNA).
The vector was called AAV-VMD2-fRDH5. It used an AAV2 vector with three capsid mutations and included a regulatory sequence intended to drive RDH5 expression in the RPE. The treatment was delivered by subretinal injection, placing the vector in the space beneath the retina and close to the RPE cells where RDH5 normally functions.
Twelve RDH5-/- cats received the treatment. The investigators then used several complementary methods to determine whether the introduced gene was expressed and whether it affected the disease features. These included retinal tissue staining, high-performance liquid chromatography to assess visual-cycle-related molecules, electroretinography (ERG) to measure retinal responses to light, optical coherence tomography (OCT) imaging, and detailed retinal tissue sectioning.
Key findings: improved recovery of rod and cone function
The central finding was that expression of the RDH5 transgene improved functional recovery in both rods and cones after light exposure. Rods are the photoreceptors that are especially important for vision in dim conditions, while cones support central and color vision and function best in brighter light.
This result is particularly meaningful in the context of RDH5-related fundus albipunctatus. Because RDH5 contributes to regenerating the visual pigment needed after light exposure, impaired recovery of photoreceptor function is a biologically relevant target. Delivering a functional RDH5 gene to the RPE appears to have supported this process in the treated animals.
The findings also suggested that treatment could help slow or halt degeneration in the feline area centralis. This is the region of the cat retina considered analogous to the human macula. While the abstract describes this structural result as promising rather than definitive, it is notable because macular degeneration is one of the most concerning potential features for a subset of people with RDH5 mutations.
Together, the functional ERG results and structural assessments strengthen the rationale for the approach. Rather than measuring only one outcome, the study examined whether gene delivery could influence the underlying visual-cycle defect, light-response recovery, and retinal health.
What this could mean for treatment development
There is currently an unmet need for therapies that directly address the genetic cause of RDH5-associated retinopathy. This research supports RDH5 gene augmentation as a potential strategy: replacing the missing or nonfunctional gene activity in the RPE, where the visual-cycle defect originates.
The use of a large-animal model is also an important step in therapeutic development. Cat eyes and retinas allow investigators to evaluate subretinal delivery, retinal imaging, functional testing, and tissue-level effects in ways that can help inform later-stage development. The study shows that the selected vector and delivery method can produce RDH5 transgene expression and meaningful biological effects in this disease model.
For families affected by fundus albipunctatus, these results do not represent a treatment that is currently available in clinical care. They do, however, provide evidence that the disease mechanism may be addressable with a targeted genetic medicine. The focus on both rod and cone recovery may be especially relevant to the range of visual difficulties that can occur in RDH5-associated disease.
Looking ahead
This study moves RDH5 gene therapy forward by showing phenotype rescue in an RDH5-/- cat model. Future research can build on these findings by further defining the durability of treatment effects, the degree of protection in the area centralis, and the path toward studies in people.
More broadly, the work illustrates a growing direction in inherited retinal disease research: developing treatments that restore a missing gene’s function before substantial retinal degeneration occurs. For RDH5-associated fundus albipunctatus, gene augmentation now has supportive preclinical evidence as a potential route toward preserving retinal function and protecting central vision.